# Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas

> **NCT03134131** · — · NO_LONGER_AVAILABLE · sponsor: **Jazz Pharmaceuticals**

## Conditions studied

- Glioma

## Interventions

- **DRUG:** ONC201

## Key facts

- **NCT ID:** NCT03134131
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2022-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03134131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03134131, "Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03134131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*